Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/sj.leu.2403536 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Differential Complement, Fc and Chemokine Receptor Expression of B Cells in IgG4-Related Pancreatobiliary Disease and Primary Sclerosing Cholangitis and Its Relevance for Targeting B Cell Pathways in Disease.
Biomedicines
December 2024
Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, South Parks Road, Oxford OX1 3SY, UK.
Immune-mediated liver and biliary conditions, such as IgG4-related pancreatobiliary disease (IgG4-PB) and a subset of primary sclerosing cholangitis (PSC- high(h)IgG4), exhibit increased IgG4 levels in the blood. The relative expression of IgG4+ and IgG1+ B cells in the blood and the expression of complement and Fc receptors on these IgG1+ and IgG4+ B cells in IgG4-PB and PSC have not been previously described. We hypothesised that the patterns of expression of these cells and their receptors would differ, are relevant to disease pathogenesis and may represent therapeutic targets.
View Article and Find Full Text PDFPharmacokinetics, Pharmacodynamics, Bioavailability, and Immunogenicity of Obexelimab Following Subcutaneous Administration in Healthy Japanese and Non-Japanese Volunteers.
Adv Ther
December 2024
Zenas BioPharma, 1000 Winter St, Suite 1200, Waltham, MA, 02451, USA.
Introduction: Obexelimab is an investigational, bifunctional, non-depleting, humanized monoclonal antibody that binds CD19 and FcγRIIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells. In clinical trials, intravenous (IV) administration of obexelimab has been well-tolerated, and demonstrated clinical activity in patients with rheumatoid arthritis, systemic lupus erythematosus, and immunoglobulin G4-related disease. This study was performed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of obexelimab following subcutaneous (SC) administration, and compare PK/PD profiles between healthy Japanese and non-Japanese volunteers.
View Article and Find Full Text PDFInhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma.
J Immunother Cancer
October 2024
Laboratory of Host Defenses, Department of Biological Sciences, KAIST, Daejeon 34141, Republic of Korea
Article Synopsis
- Certain cancers, like glioblastoma (GBM), show resistance to immune therapies due to low mutation rates and a lack of immune response features, prompting research into enhancing T cells that possess stem-like properties.
- Studies in mice tested the effectiveness of anti-PD-1 immunotherapy combined with strategies to maintain the activity of these stem-like T cells, revealing improvements in survival and immune response.
- Results indicated that combining anti-PD-1 therapy with other treatments significantly increases the effectiveness of CD8 T cells, with the presence of tumor-specific memory T cells exhibiting strong stemness driving this enhanced antitumor response.
An Expression Quantitative Trait Locus of Fc Gamma Receptor Genes is Associated with Anti-Malarial IgG Responses and Infection Levels in Burkinabe Families.
J Infect Dis
October 2024
Aix Marseille Univ, INSERM U1090, TAGC, Marseille 13009, France.
Background: The interaction between antibodies and Fc gamma receptors (FcγRs) plays a critical role in regulating immune responses to Plasmodium falciparum. Polymorphisms in genes encoding FcγRs influence the host's capacity to control parasite infection. This study investigates whether non-coding variants influencing FcγR expression are associated with anti-malarial immunization and infection traits.
View Article and Find Full Text PDFCirculating B Cells Display Differential Immune Regulatory Molecule Expression in Granulomatosis with Polyangiitis.
Clin Exp Immunol
October 2024
Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Granulomatosis with polyangiitis (GPA) is a B cell-mediated, relapsing, autoimmune disease. There is a need for novel therapeutic approaches and relapse markers to achieve durable remission. B cells express immune regulatory molecules that modulate their activation and maintain tolerance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!